Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates
- 5 May 2025
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (11) , 2709-2713
Abstract
INTRODUCTION: Screen failure is a major challenge in the enrollment of metabolic dysfunction-associated steatohepatitis (MASH) randomized controlled trials (RCTs), but its impact has not been systematically assessed. METHODS: We searched PubMed and the Cochrane Library databases for phase ≥2 RCTs of MASH pharmacotherapies in adults using histological inclusion criteria. Screen failure rates (SFRs) were pooled using a generalized linear mixed model. RESULTS: Of 67 included RCTs, 58 reported enrollment data. The pooled SFR was 56.28% (95% confidence interval 50.14–62.23) in 44,949 individuals. The most common reason for screen failure was ineligibility. SFR was higher in more recent trials, globally conducted trials, and trials funded by pharmaceutical companies. Meta-regressions showed an increase in SFR over time and with more trial sites. DISCUSSION: Evidence-based strategies to reduce the high SFR in MASH clinical trials are urgently needed.Keywords
This publication has 14 references indexed in Scilit:
- Underrepresentation of Asians in diagnostic test development and drug trials in MASLDJournal of Hepatology, 2025
- Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trialsJHEP Reports, 2025
- Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysisHepatology, 2025
- WED-199 Optimizing MASLD trial recruitment: LiverPRO vs. FIB-4 in reducing false positives and unnecessary biopsiesJournal of Hepatology, 2024
- Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failuresAlimentary Pharmacology & Therapeutics, 2024
- NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trialsJournal of Hepatology, 2023
- Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysisHepatology, 2023
- Clinical Trial Landscape in NASHClinical Gastroenterology and Hepatology, 2023
- Challenges and opportunities in NASH drug developmentNature Medicine, 2023
- Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectivenessJBI Evidence Implementation, 2015